Ran Frenkel - Net Worth and Insider Trading
Ran Frenkel Net Worth
The estimated net worth of Ran Frenkel is at least $115,941 dollars as of 2024-04-29. Ran Frenkel is the EVP, Chief Dev. Officer of Karyopharm Therapeutics Inc and owns about 101,703 shares of Karyopharm Therapeutics Inc (KPTI) stock worth over $115,941. Details can be seen in Ran Frenkel's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ran Frenkel has not made any transactions after 2022-02-17 and currently still holds the listed stock(s).
Transaction Summary of Ran Frenkel
Ran Frenkel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ran Frenkel owns 1 companies in total, including Karyopharm Therapeutics Inc (KPTI) .
Click here to see the complete history of Ran Frenkel’s form 4 insider trades.
Insider Ownership Summary of Ran Frenkel
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc | 2022-02-17 | EVP & WW Development Operations |
Ran Frenkel Latest Holdings Summary
Ran Frenkel currently owns a total of 1 stock. Ran Frenkel owns 101,703 shares of Karyopharm Therapeutics Inc (KPTI) as of February 17, 2022, with a value of $115,941.
Latest Holdings of Ran Frenkel
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc | 2022-02-17 | 101,703 | 1.14 | 115,941 |
Holding Weightings of Ran Frenkel
Ran Frenkel Form 4 Trading Tracker
According to the SEC Form 4 filings, Ran Frenkel has made a total of 6 transactions in Karyopharm Therapeutics Inc (KPTI) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Karyopharm Therapeutics Inc is the sale of 2,929 shares on February 17, 2022, which brought Ran Frenkel around $35,500.
Insider Trading History of Ran Frenkel
- 1
Ran Frenkel Trading Performance
GuruFocus tracks the stock performance after each of Ran Frenkel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ran Frenkel is -17.04%. GuruFocus also compares Ran Frenkel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ran Frenkel within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ran Frenkel's insider trading performs compared to the benchmark.
Performance of Ran Frenkel
Average Return
-70.82%
Outperforming Transactions
0%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -8.94 | -17.04 | -60.6 | -70.82 | -39.64 | -26.34 |
| Relative Return to S&P 500(%) | -9.5 | -17.28 | -56.72 | -69.17 | -46.14 | -34.19 |
Ran Frenkel Ownership Network
Ownership Network List of Ran Frenkel
Ownership Network Relation of Ran Frenkel
Ran Frenkel Owned Company Details
What does Karyopharm Therapeutics Inc do?
Who are the key executives at Karyopharm Therapeutics Inc?
Ran Frenkel is the EVP & WW Development Operations of Karyopharm Therapeutics Inc. Other key executives at Karyopharm Therapeutics Inc include EVP & Chief Medical Officer Reshma Rangwala , director & President and CEO Richard A. Paulson , and EVP & CFO & Treasurer Michael Mason .
Karyopharm Therapeutics Inc (KPTI) Insider Trades Summary
Over the past 18 months, Ran Frenkel made no insider transaction in Karyopharm Therapeutics Inc (KPTI). Other recent insider transactions involving Karyopharm Therapeutics Inc (KPTI) include a net sale of 199,037 shares made by Richard A. Paulson , a net sale of 66,291 shares made by Michael Mason , and a net sale of 47,442 shares made by Sohanya Roshan Cheng .
In summary, during the past 3 months, insiders sold 255,827 shares of Karyopharm Therapeutics Inc (KPTI) in total and bought 0 shares, with a net sale of 255,827 shares. During the past 18 months, 423,673 shares of Karyopharm Therapeutics Inc (KPTI) were sold and 41,140 shares were bought by its insiders, resulting in a net sale of 382,533 shares.
Karyopharm Therapeutics Inc (KPTI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Karyopharm Therapeutics Inc Insider Transactions
Ran Frenkel Mailing Address
Above is the net worth, insider trading, and ownership report for Ran Frenkel. You might contact Ran Frenkel via mailing address: C/o Karyopharm Therapeutics Inc., 85 Wells Avenue, 2nd Floor, Newton Ma 02459.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
